Research Paper Volume 11, Issue 7 pp 2138—2150

MiR-204 reduces cisplatin resistance in non-small cell lung cancer through suppression of the caveolin-1/AKT/Bad pathway

Figure 2. Role of CAV-1 in regulating cisplatin sensitivity in NSCLC. (A) Expression of CAV-1 in A549, CR-A549, PC9, and CR-PC9 cells was detected by western blot analysis. (B) Effect of the CAV-1 plasmid (2 μg/ml) and CAV-1 siRNA (50 pmol/ml) on the expression level of CAV-1 in A549, CR-A549, PC9, and CR-PC9 cells. (C) Effect of CAV-1 siRNA (50 pmol/ml) on the sensitivity of CR-A549 and CR-PC9 cells to cisplatin (8 μM) treatment. *P<0.05 vs. Cisplatin+NCO group. (D) Effect of the CAV-1 plasmid (2 μg/ml) on the sensitivity of A549 and PC9 cells to cisplatin (8 μM) treatment. *P<0.05 vs. Cisplatin+NCO group.